Promentis Pharmaceuticals Inc., a Milwaukee company that is developing drugs to treat schizophrenia and other psychiatric disorders, has raised an additional $17.2 million from investors, bringing the total in its third round of financing to $26 million.
The company previously raised $8.8 million in the round.
The money will be used partly to finance the second phase of clinical trials for the company’s most promising compound. Read the full story here.